Abstracts tagged "Bone density"

Abstract Number: 1234 • 2013 ACR/ARHP Annual Meeting
Effects Of Biological Therapy In Bone Metabolism In Patients With Chronic Inflammatory Arthropathies
Maria Victoria Hernández¹, Andrea Cuervo², Pilar Peris¹, Ana Monegal¹, Raimon Sanmarti¹, Juan D. Cañete¹ and Nuria Guañabens¹, ¹Rheumatology, Hospital Clínic of Barcelona. IDIBAPS. University of Barcelona, Barcelona, Spain, ²Arthritis Unit. Rheumatology Department, Hospital Clínic of Barcelona, Barcelona, Spain
Background/Purpose: The efficacy of biological agents in the treatment of chronic inflammatory arthropathies is well known, however, the effect of this therapy in bone metabolism…
Abstract Number: 863 • 2013 ACR/ARHP Annual Meeting
Romosozumab Administration Is Associated With Significant Improvements In Lumbar Spine and Hip Volumetric Bone Mineral Density and Content Compared With Teriparatide
H K Genant¹, S Boonen², M A Bolognese³, C Mautalen⁴, J P Brown⁵, C Recknor⁶, S Goemaere⁷, K Engelke⁸, Y-C Yang⁹, M Austin⁹, A Grauer⁹ and C Libanati⁹, ¹UCSF & Synarc Inc., San Francisco, CA, ²Leuven University Division of Geriatric Medicine, Leuven, Belgium, ³The Bethesda Health Research Center, Bethesda, MD, ⁴Centro de Osteopatias Medicas, Buenos Aires, Argentina, ⁵CHU de Québec Research Centre and Laval University, Québec, QC, Canada, ⁶United Osteoporosis Centers, Gainesville, GA, ⁷Ghent University Hospital, Ghent, Belgium, ⁸Synarc Germany, Hamburg, Germany, ⁹Amgen Inc., Thousand Oaks, CA
Background/Purpose: Sclerostin is an osteocyte-derived inhibitor of osteoblast activity. Romosozumab, a monoclonal antibody to sclerostin stimulates bone formation and decreases bone resorption. In a phase…
Abstract Number: 864 • 2013 ACR/ARHP Annual Meeting
Further Reduction In Nonvertebral Fracture Rate Is Observed Following 3 Years Of Denosumab Treatment: Results With Up To 7 Years In The Freedom Extension
Jonathan D. Adachi¹, Serge Ferrari², Carol Zapalowski³, Paul D. Miller⁴, Jean-Yves Reginster⁵, Ove Törring⁶, Nadia Daizadeh³, Andrea Wang³, Cynthia O'Malley⁷, Rachel B. Wagman³ and E. Michael Lewiecki⁸, ¹McMaster University, Hamilton, ON, Canada, ²Geneva University Hospital, Geneva, Switzerland, ³Amgen Inc., Thousand Oaks, CA, ⁴Colorado Center for Bone Research, Lakewood, CO, ⁵University of Liège, Liège, Belgium, ⁶Karolinska Institutet, Södersjukhuset, Stockholm, Sweden, ⁷Center for Observational Research, Amgen, Inc., Thousand Oaks, CA, ⁸New Mexico Clinical Research & Osteoporosis Center, Albuquerque, NM
Further Reduction in Nonvertebral Fracture Rate Is Observed Following 3 Years of Denosumab Treatment: Results With up to 7 Years in the FREEDOM ExtensionBackground/Purpose: Some…
Abstract Number: 865 • 2013 ACR/ARHP Annual Meeting
Vertebral Fractures In The 3 Year Period Following Steroid Initiation Among Children With Chronic Illnesses
Johannes Roth¹, Jinhui Ma¹, David A. Cabral², Peter B. Dent³, Janet E. Ellsworth⁴, Adam M. Huber⁵, Kristin M. Houghton², Roman Jurencak¹, Bianca A. Lang⁵, Maggie Larche³, Claire MA Leblanc⁶, Brian Lentle², MaryAnn Matzinger¹, Paivi M. Miettunen⁷, Kiem Oen⁸, Claire Saint-cyr⁹, Rosie Scuccimarri¹⁰, Nazih Shenouda¹, Leanne M. Ward¹ and The Canadian STOPP Consortium¹¹, ¹University of Ottawa, Ottawa, ON, Canada, ²University of British Columbia, Vancouver, BC, Canada, ³McMaster University, Hamilton, ON, Canada, ⁴University of Alberta, Edmonton, AB, Canada, ⁵Dalhousie University, Halifax, NS, Canada, ⁶McGill University, Montréal, QC, Canada, ⁷University of Calgary, Calgary, AB, Canada, ⁸University of Manitoba, Winnipeg, MB, Canada, ⁹Université de Montréal, Montreal, QC, Canada, ¹⁰McGill University, Montreal, QC, Canada, ¹¹National Pediatric Bone Health Working Group, Ottawa, ON, Canada
Background/Purpose: : To describe the pattern and frequency of incident vertebral fractures (VF) in glucocorticoid (GC)-treated children and to determine the clinical factors at baseline…
Abstract Number: 373 • 2013 ACR/ARHP Annual Meeting
Menopause Occurs Earlier and Is An Independent Risk Factor For Osteoporosis In Women With Rheumatoid Arthritis
Michael Cocker¹, Alexander Oldroyd² and Marwan Bukhari³, ¹Rheumatology, Royal Lancaster Infirmary, Lancaster, United Kingdom, ²Lancaster Medical School, Lancaster University, Lancaster, United Kingdom, ³Department of Rheumatology, Royal Lancaster Infirmary, Lancaster, United Kingdom
Background/Purpose: Rheumatoid arthritis (RA) and early menopause (
Abstract Number: 2262 • 2013 ACR/ARHP Annual Meeting
Antibody To Malondialdehyde-Acetaldehyde Adducts (MAA) Is a Biomarker Of Inflammation and Is Correlated With The Disease Activity In Rheumatoid Arthritis
Kathleen Young¹, Dathe Benissan-Messan², Michael J. Duryee³, Daniel Anderson⁴, Liron Caplan^5,6, Lisa A. Davis^7,8,9, Harlan Sayles⁴, Carlos D. Hunter³, Lynell W. Klassen¹⁰, James R. O'Dell¹¹, Ted R. Mikuls⁴ and Geoffrey M Thiele¹², ¹Int Med/Sec of Rheum/Immun, University of Nebraska Medical Center, Omaha, NE, ²Internal Medicine, University of Nebraska Medical Center, Omaha, NE, ³Internal Medicine Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE, ⁴Omaha VA Medical Center and University of Nebraska Medical Center, Omaha, NE, ⁵Department of Medicine, Denver Veterans Affairs Medical Center, Denver, CO, ⁶Department of Medicine, University of Colorado School of Medicine, Aurora, CO, ⁷Division of Rheumatology, Univ. of Colorado Sch. of Medicine, Aurora, CO, ⁸Division of Rheumatology, Denver Health and Hospital Authority, Denver, CO, ⁹Denver Veterans Affairs Medical Center, Denver, CO, ¹⁰Dept of Internal Medicine, Omaha VA Medical Center and University of Nebraska Medical Center, Omaha, NE, ¹¹Dept of Internal Medicine, University of Nebraska Medical Center, Omaha, NE, ¹²Internal Medicine, Omaha VA Medical Center and University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Cardiovascular disease (CVD) is a major cause of morbidity and mortality in patients with rheumatoid arthritis (RA). While there are many markers used…
Abstract Number: 1785 • 2013 ACR/ARHP Annual Meeting
Structural Determinants Of Low Vertebral Strength In Pediatric Systemic Lupus Erythematosus
Jon M. Burnham¹, Babette S. Zemel¹, David C. Lee², Tony M. Keaveny³ and Mary Beth Leonard¹, ¹Pediatrics, The Children's Hospital of Philadelphia and the Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, ²O.N. Diagnostics, LLC, Berkeley, CA, ³Founder and Chief Science Officer, University of California, Berkeley, CA and O.N. Diagnostics, LLC, Berkeley, CA
Background/Purpose: Children with systemic lupus erythematosus (SLE) are at high risk for bone fragility. Studies in pediatric SLE using two-dimensional lumbar spine (LS) dual X-ray…
Abstract Number: 1548 • 2013 ACR/ARHP Annual Meeting
Effect Of TNF Inhibitors On Bone Mineral Density In Patients With Ankylosing Spondylitis- a Systematic Review and Meta-Analysis
Nisha Nigil Haroon¹, Jeevitha Srighanthan², Nayef AL Ghanim³, Robert D. Inman^4,5,6,7,8,9 and Angela Cheung¹⁰, ¹Medicine, University of Toronto, Toronto, ON, Canada, ²Osteoporosis Program, University of Toronto, Ontario, ON, Canada, ³Rheumatology, University of Toronto, Toronto, ON, Canada, ⁴Toronto Western Hospital, Toronto, ON, Canada, ⁵Rheumatology, Toronto Western Research Institute. University of Toronto, Toronto, ON, Canada, ⁶University of Toronto, Toronto, ON, Canada, ⁷Dept of Medicine/Rheumatology, Toronto Western Research Institute, University Health Network and University of Toronto, Toronto, ON, Canada, ⁸U of Toronto, Toronto, ON, Canada, ⁹Dept of Medicine/Rheumatology, The Arthritis Program, Toronto Western Hospital and Division of Rheumatology, Toronto Western Hospital and University of Toronto, Toronto, ON, Canada, ¹⁰Department of Medicine, University of Toronto, Toronto, ON, Canada
Background/Purpose: Patients with ankylosing spondylitis (AS) are susceptible to osteoporosis (OP) and have high fracture risk. Currently, no specific strategies are established to treat OP…
Abstract Number: 1237 • 2013 ACR/ARHP Annual Meeting
Denosumab Leads To Significantly Greater Increases In Bone Mineral Density Than Ibandronate and Risedronate In Postmenopausal Women At High Risk For Fracture Who Were Previously Treated With An Oral Bisphosphonate
Jacques P. Brown¹, Michael A. Bolognese², Pei-Ran Ho³, Jesse Hall³, Christian Roux⁴, Henry G. Bone⁵, Sydney Bonnick⁶, Joop van den Bergh⁷, Irene Ferreira⁸, Prayashi Ghelani⁹, Paula Dakin³, Rachel B. Wagman³ and Chris Recknor¹⁰, ¹CHU de Québec Research Centre and Laval University, Quebec City, QC, Canada, ²Bethesda Health Research Center, Bethesda, MD, ³Amgen Inc., Thousand Oaks, CA, ⁴Paris Descartes University, Paris, France, ⁵Michigan Bone and Mineral Clinic, Detroit, MI, ⁶Clinical Research Center of North Texas, Denton, TX, ⁷VieCuri Medical Centre and Maastricht University, Venlo, Netherlands, ⁸Amgen Inc., Cambridge, United Kingdom, ⁹Ovatech Solutions, London, United Kingdom, ¹⁰United Osteoporosis Centers, Gainesville, GA
Denosumab Leads to Significantly Greater Increases in Bone Mineral Density Than Ibandronate and Risedronate in Postmenopausal Women at High Risk for Fracture Who Were Previously…
Abstract Number: 1239 • 2013 ACR/ARHP Annual Meeting
The Effects Of Hyperparathyroidism On Body Mass Index and Bone Mineral Density- An Observational Case-Control Study
Chris Varley¹, Alexander Oldroyd² and Marwan Bukhari³, ¹Lancaster Medical School, Lancaster University, Llandudno, United Kingdom, ²Lancaster Medical School, Lancaster University, Lancaster, United Kingdom, ³Department of Rheumatology, Royal Lancaster Infirmary, Lancaster, United Kingdom
Background/Purpose: Hyperparathyroidism is associated with reduced bone mineral density (BMD) and increased fracture risk. A previous study from this group has shown that bone loss…
Abstract Number: 1222 • 2013 ACR/ARHP Annual Meeting
Analysis Of Corelation Of Bone Mineral Density Of Spine With Other Sites In Ankylosing Spondylitis As Compared To Rheumatoid Arthritis and Control Populations
Janie Bruce¹ and Vikas Majithia^2,3, ¹Div of Rheumatology, University of Mississippi School of Medicine, Jackson, MS, ²Div of Rheumatology, University of Mississippi Medical Center, Jackson, MS, ³G.V. "Sonny" Montogomery VA Medical Center, Jackson, MS
Background/Purpose: Bone mineral density (BMD) at the 3 central sites usually correlates with each other but the effect of disease states on this correlation is…
Abstract Number: 1230 • 2013 ACR/ARHP Annual Meeting
Analysis Of Fracture Risk Assessment Score (FRAX) Correlation With Bone Mineral Density (BMD) In Males and Post-Menopausal Females
Vikas Majithia¹ and Khush Aujla², ¹Div of Rheumatology, University of Mississippi Medical Center, Jackson, MS, ²Division of Rheumatology, University of Mississippi School of Medicine, Jackson, MS
Background/Purpose: Fracture Risk Assessment Tool (FRAX) is a useful clinical tool for assessment of fracture risk and a major development in evaluation of osteoporosis. Its…
Abstract Number: 1970 • 2012 ACR/ARHP Annual Meeting
Utility of Spine Bone Mineral Density in Fracture Prediction within the Fracture Risk Assessment Tool (FRAX)
Tristan Blackburn¹, Diantha Howard² and Edward S. Leib³, ¹Rheumatology, Fletcher Allen Health Care, University of Vermont College of Medicine, Burlington, VT, ²Medicine, Vermont Center for Clinical and Translational Science, Burlington, VT, ³Medicine, Fletcher Allen Health Care, University of Vermont College of Medicine, Burlington, VT
Background/Purpose: Predicting which individuals are at risk to experience a fracture and modify that risk is important in preventative health. The WHO’s Fracture Risk Assesment…
Abstract Number: 1958 • 2012 ACR/ARHP Annual Meeting
Bone Mineral Density in Lupus Erythematosus Women One Year After Rituximab Therapy
Claudia Mendoza-Pinto¹, Mario Garcia-Carrasco¹, Mario Jiménez-Hernández¹, Alma Rodríguez-Gallegos², Socorro Méndez-Martínez¹ and Aurelio Lopez-Colombo³, ¹Systemic Autoimmune Disease, HGR 36 CMN Manuel Ávila Camacho, Instituto Mexicano del Seguro Social, Puebla, Mexico, ²Laboratorios Clínicos de Puebla, Puebla, Mexico, ³Research Departament, Delegación Estatal, Instituto Mexicano del Seguro Social, Puebla, Mexico
Background/Purpose: Low bone mineral density (BMD) and osteoporosis may be significant complications in patients with systemic lupus erythematosus (SLE). Recent studies have shown that biologic therapy could…
Abstract Number: 1557 • 2012 ACR/ARHP Annual Meeting
What Percentage of Postmenopausal Women Younger Than Age 65 Years Have Low Bone Mineral Density At a Family Health Center?
Marvin Vaishnani¹ and Feyrouz T. Al-Ashkar², ¹Rheumatic and Immunologic diseases, Cleveland Clinic,Lorain Institute, Lorain, OH, ²Rheumatic and Immunologic Diseases, Cleveland Clinic,Lorain Institute, Lorain, OH
Background/Purpose: Many younger women, < 65 years of age may have low bone mineral density (BMD) that remains undetected in clinical practice due to following…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].